CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 35 enrolled
Drug / intervention
Doxazosin +1 moredrug
Likely dose
Doxazosin 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00880997
NCT00880997Phase 1Completed
CompareCT.gov

Doxazosin, An Alpha-1 Adrenergic Antagonist, for Cocaine Dependence: Pilot Study

Baylor College of Medicine·interventional·Posted Apr 14, 2009·Updated Aug 22, 2019

In Brief

A Phase 1 clinical trial evaluating Doxazosin and Placebo for Cocaine Dependence. Completed, enrolled 35 participants across 1 site.

Detailed Summary

Doxazosin, an alpha 1-adrenergic receptor, may play an important role in cocaine addiction in humans. This study will evaluate the effectiveness of doxazosin in preventing drug relapse among cocaine dependent participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 14, 2009
Enrollment StartSep 1, 2009
Primary CompletionApr 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.2 years ago

Interventions

Doxazosindrug

Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows: 1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group) 2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group) Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17.

Placeboother

Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.